Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.67 | -2.66% | -0.02 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
1,2,3 Retracement Bearish | Bearish Swing Setup | -2.66% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.66% | |
NR7 | Range Contraction | -2.66% | |
Narrow Range Bar | Range Contraction | -2.66% | |
Inside Day | Range Contraction | -2.66% | |
Wide Bands | Range Expansion | -2.66% | |
Oversold Stochastic | Weakness | -2.66% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | -0.16% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.16% | |
Calm After Storm | Range Contraction | -0.16% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Get this analysis on your stocks daily!
- Earnings date: 11/28/2022
Aridis Pharmaceuticals Inc. Description
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Infectious Diseases Immunotherapy Antibodies Monoclonal Antibody Monoclonal Antibodies Infection Bacterial Infections Bacterial Disease Pneumonia Staphylococcus Aureus Pathogenic Bacteria Human Monoclonal Antibodies Drug Resistance Pseudomonas Aeruginosa Targeted Immunotherapy Immunoglobulin M
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.94 |
52 Week Low | 0.5722 |
Average Volume | 1,021,815 |
200-Day Moving Average | 1.22 |
50-Day Moving Average | 1.03 |
20-Day Moving Average | 1.05 |
10-Day Moving Average | 0.82 |
Average True Range | 0.19 |
RSI | 37.50 |
ADX | 36.31 |
+DI | 8.65 |
-DI | 28.14 |
Chandelier Exit (Long, 3 ATRs) | 1.08 |
Chandelier Exit (Short, 3 ATRs) | 1.14 |
Upper Bollinger Bands | 1.61 |
Lower Bollinger Band | 0.50 |
Percent B (%b) | 0.17 |
BandWidth | 105.72 |
MACD Line | -0.12 |
MACD Signal Line | -0.06 |
MACD Histogram | -0.0595 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.73 | ||||
Resistance 3 (R3) | 0.73 | 0.71 | 0.73 | ||
Resistance 2 (R2) | 0.71 | 0.70 | 0.71 | 0.72 | |
Resistance 1 (R1) | 0.70 | 0.69 | 0.69 | 0.70 | 0.72 |
Pivot Point | 0.68 | 0.68 | 0.67 | 0.68 | 0.68 |
Support 1 (S1) | 0.67 | 0.67 | 0.66 | 0.67 | 0.66 |
Support 2 (S2) | 0.65 | 0.66 | 0.65 | 0.65 | |
Support 3 (S3) | 0.64 | 0.65 | 0.65 | ||
Support 4 (S4) | 0.64 |